Imran Ahmad, MD, outlines the diagnosis and management of diabetic macular edema, emphasizing screening gaps, socioeconomic barriers, and treatment options in developing countries. He reviews evidence-based protocols, the role of anti-VEGF therapies like aflibercept, ranibizumab, and off-label bevacizumab, and how treatment choices shift when affordability and access are limited.
Jean-Francois Korobelnik, MD, professor of ophthalmology, University Hospital of Bordeaux, explained findings of an analysis of the Phase 3 PULSAR trial designed to assess disease activity control. Dr…
Richard Gale, MBChB, PhD, professor of ophthalmology, Hull York Medical School, UK, presents long-term real-world outcomes of intravitreal aflibercept 8 mg in patients with diabetic macular edema. Over…
Charles Wykoff, MD, PhD, joins Diane Bovenkamp, PhD, for a Macular Chat hosted by BrightFocus Foundation and ASRS to discuss the current landscape and future of wet age-related…
Sean Adrean, MD, Retina Consultants of Orange County, describes results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of baseline visual acuity…
Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when long-term high blood sugar damages retinal blood vessels, causing them…
Kenneth C. Fan, MD, MBA, Retinal Consultants of Texas, discusses how increased doses of aflibercept can be used to treat patients with wet age-related macular degeneration and diabetic…
Deepak Sambhara, MD, Eye Clinic of Wisconsin, discusses results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of central retinal thickness on…
Diana Do, MD, professor of ophthalmology and vice chair for clinical affairs, Byers Eye Institute, Stanford University, discusses real-world data presented at the American Academy of Ophthalmology showing…
Andrew Chang, MBBS, PhD, consultant ophthalmologist and head of Ophthalmology, Sydney Eye Hospital, Australia, shares real-world experience using 8-mg intravitreal aflibercept for neovascular age-related macular degeneration and reports…
Kelvin Teo, MBBS, PhD, senior consultant, Advanced Eye Clinic & Surgery, adjunct associate professor, Duke NUS Eye ACP, Singapore, presents real-world data showing that a single 8-mg dose…
Wet age-related macular degeneration (AMD) is a chronic, progressive eye disease marked by abnormal blood vessel growth beneath the retina. These fragile vessels can leak fluid or blood…
Starting diabetic macular edema treatment with bevacizumab and switching to aflibercept if needed offers nearly identical vision outcomes to aflibercept monotherapy, but at a far lower cost. A…
Omar Krad, MD, shares his practical approach to cataract surgery in patients with wet macular degeneration. This case involves a diabetic, hyperopic patient with vision limited to counting…
The video features an interview with Tien Y. Wong, MD, PhD, Tsinghua University, about a post-hoc analysis from the PULSAR randomized trial evaluating high-dose aflibercept (8 mg) in…
Anti-VEGF injections are a common treatment for wet age-related macular degeneration (AMD), aimed at preserving or even improving vision by stopping abnormal blood vessel growth under the macula.…
Charles C. Wykoff, MD, highlights both the success and the limitations of current treatments for wet AMD. While anti-VEGF therapies are effective at controlling bleeding and leakage in…
Age-related macular degeneration (AMD) is the leading cause of vision loss in older Americans, affecting the central part of the retina called the macula. Alla Goldberg, MD, a…
Mark R. Barakat, MD, founder and director of research, Retina Macula Institute of Arizona, discusses an analysis of the Phase 2/3 PHOTON trial. Dr Barakat explained that pre-dose…
Intravitreal injections are a routine and highly effective treatment used to stabilize or restore vision in patients with diabetic eye disease, age-related macular degeneration, and retinal vein occlusions.…
In this episode of RetinUp, hosts John Kitchens, MD, and Scott Krzywonos discuss the new CMS GLOBE Model, a Medicare Part B drug pricing demonstration project, and the…
In an interview conducted at the Association for Research in Vision and Ophthalmology Annual Meeting, May 5-9, 2023, Jordana Fein, MD, MS, Retina Group of Washington Fairfax, Virginia,…
